Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
XERS Stock Chart & Stats
$9.08
<$0.01(0.15%)
At close: 4:00 PM EST
$9.08
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$3.14 - $10.08
Previous CloseN/A
Volume530.95K
Average Volume (3M)2.20M
Market Cap
$1.21B
Enterprise ValueN/A
Total Cash (Recent Filing)$91.60M
Total Debt (Recent Filing)$38.19M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding165,924,290
10 Day Avg. Volume2,116,415
30 Day Avg. Volume2,197,287
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)-16.80
Price to Sales (P/S)2.45
P/FCF Ratio-13.15
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$12.33Price Target Upside35.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial PerformanceXeris Biopharma reported another strong quarter, achieving GAAP profitability and demonstrating solid commercial performance.
Market ExpansionStronger-than-expected Recorlev volume growth driven by increased penetration into the difficult-to-control type-2 diabetes market.
Revenue GrowthRecorlev remains the core growth driver, generating net revenue of $37.0M, up 109% year over year.
Bears Say
Commercial Execution RiskRisks to our thesis include commercial execution risk, which could impact future growth projections.
Competitive PressureKeveyis faced a modest revenue decrease due to generic competition, which could pose challenges for market share retention.
Regulatory And Clinical RisksAcknowledgement of execution risks due to nascent recognition of this patient population and potential regulatory hurdles.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $3.14 and its highest was $10.08 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.21B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Mar 11, 2026 which is in 75 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.006 by -$0.006.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 165,924,290 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of $0 in its last earnings report, missing expectations of $0.006. Following the earnings report the stock price went down -21.884%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (35.79% Upside)
$12.33 (35.79% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 671.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $976.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.89%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for the treatment of chronic and acute diseases. The company primarily operates in the pharmaceutical sector, specializing in formulation technologies that allow for the delivery of biologics and other complex drugs. Xeris is known for its proprietary formulations of injectable medications, including its flagship product, XeriJect, which aims to enhance the convenience and efficacy of drug delivery for patients with diabetes and other conditions.
XERS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Xeris Biopharma's strong financial performance with record revenue growth and successful product performance, particularly for RECORLEV. However, there are increased expenses and potential competitive challenges on the horizon. Despite these concerns, the company's positive financial milestones and strategic growth plans suggest an optimistic outlook.View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
$12.33
▲(35.79% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―
Ownership Overview
5.60% Insiders
10.52% Mutual Funds
11.57% Other Institutional Investors
58.26% Public Companies and
Individual Investors